Published in AJNR Am J Neuroradiol on May 01, 2006
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD): a single entity? Neurology (2009) 1.27
CSF1R mutations link POLD and HDLS as a single disease entity. Neurology (2013) 1.27
Adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia: report of five cases and a new mutation. J Neurol (2012) 1.10
Insights into the dynamics of hereditary diffuse leukoencephalopathy with axonal spheroids. Neurology (2008) 1.07
An adult-onset leukoencephalopathy with axonal spheroids and pigmented glia accompanied by brain calcifications: a case report and a literature review of brain calcifications disorders. J Neurol (2013) 0.93
Rapid onset frontal leukodystrophy with decreased diffusion coefficient and neuroaxonal spheroids. J Neurol (2009) 0.87
The many ways to frontotemporal degeneration and beyond. Neurol Sci (2007) 0.83
A clinicopathological and genetic study of sporadic diffuse leukoencephalopathy with spheroids: a report of two cases. Neuropathol Appl Neurobiol (2013) 0.75
Sporadic diffuse leucoencephalopathy with axonal spheroids: report of a profuse and rapid cortical-spinal degeneration. Neurol Sci (2011) 0.75
Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial. Lancet (2001) 3.64
Neurotoxicity of a prion protein fragment. Nature (1993) 3.38
Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett (1989) 2.69
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol (2000) 2.60
Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial. JPEN J Parenter Enteral Nutr (2000) 2.36
Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem (2009) 2.34
Sporadic Creutzfeldt-Jakob disease: co-occurrence of different types of PrP(Sc) in the same brain. Neurology (1999) 2.33
Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci Lett (1988) 2.26
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol (1998) 2.15
Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol (1995) 2.10
Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci U S A (1996) 1.94
Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol (2001) 1.94
Tissue handling in suspected Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases) Brain Pathol (1995) 1.86
Phenotypic variability of Gerstmann-Sträussler-Scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol (1998) 1.79
Amyloid protein of Gerstmann-Sträussler-Scheinker disease (Indiana kindred) is an 11 kd fragment of prion protein with an N-terminal glycine at codon 58. EMBO J (1991) 1.74
Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem (2000) 1.71
Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science (1997) 1.70
Amyloid fibrils in Gerstmann-Sträussler-Scheinker disease (Indiana and Swedish kindreds) express only PrP peptides encoded by the mutant allele. Cell (1994) 1.69
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol (2009) 1.68
Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc Natl Acad Sci U S A (1993) 1.68
FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res (1997) 1.66
Prion protein amyloidosis. Brain Pathol (1996) 1.64
Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A (1990) 1.63
Infantile neuroaxonal dystrophy: clinical spectrum and diagnostic criteria. Neurology (1999) 1.62
Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation. Neurology (2010) 1.59
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol (2006) 1.54
Detection of cytokeratin-19 transcripts by reverse transcriptase-polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients. Lab Invest (1997) 1.54
Revelation of a novel CLN5 mutation in early juvenile neuronal ceroid lipofuscinosis. Neuropediatrics (2007) 1.53
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 1.52
Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol (1999) 1.49
Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies. Neurology (2003) 1.46
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol (1999) 1.43
p53 and chemosensitivity. Ann Oncol (1999) 1.42
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol (2000) 1.40
[Novel approaches; improved diagnostics and therapeutics with DNA microarrays. II. Applications]. Ned Tijdschr Geneeskd (2003) 1.39
Infantile neuroaxonal dystrophy: neuroradiological studies in 11 patients. Neuroradiology (1999) 1.37
Alzheimer patients and Down patients: cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques. Neurosci Lett (1989) 1.35
A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Sträussler-Scheinker disease A117V. J Biol Chem (2000) 1.34
Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res (1999) 1.31
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res (2001) 1.30
Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res (2000) 1.26
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol (1997) 1.25
Gerstmann-Sträussler-Scheinker disease and the Indiana kindred. Brain Pathol (1995) 1.25
The fine structure of subcortical neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathol (1979) 1.24
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol (2011) 1.24
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol (2011) 1.23
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer (1998) 1.23
Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Biochem Biophys Res Commun (1993) 1.23
Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol (1997) 1.22
Gerstmann-Sträussler-Scheinker disease. II. Neurofibrillary tangles and plaques with PrP-amyloid coexist in an affected family. Neurology (1989) 1.22
Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst (1995) 1.21
Human natural killer T cells acquire a memory-activated phenotype before birth. Blood (2000) 1.20
Progressive supranuclear palsy 1979: an overview. Ital J Neurol Sci (1980) 1.20
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer (1999) 1.19
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol (2008) 1.17
Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol (1996) 1.17
Tau protein directly interacts with the amyloid beta-protein precursor: implications for Alzheimer's disease. Nat Med (1995) 1.13
Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol (1995) 1.13
Creutzfeldt-Jakob disease: Carnoy's fixative improves the immunohistochemistry of the proteinase K-resistant prion protein. Brain Pathol (2000) 1.13
Thymomas. A review of 169 cases, with particular reference to results of surgical treatment. Cancer (1986) 1.11
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol (2013) 1.11
The multilayered postconfluent cell culture as a model for drug screening. Crit Rev Oncol Hematol (2001) 1.11
Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer (2002) 1.09
Prion protein preamyloid and amyloid deposits in Gerstmann-Sträussler-Scheinker disease, Indiana kindred. Proc Natl Acad Sci U S A (1992) 1.09
Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol (2000) 1.09
Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am J Pathol (1992) 1.08
Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr (1992) 1.08
Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J Biol Chem (1994) 1.07
Prion proteins with different conformations accumulate in Gerstmann-Sträussler-Scheinker disease caused by A117V and F198S mutations. Am J Pathol (2001) 1.07
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer. Ann Oncol (1997) 1.07
Delayed spongiform leukoencephalopathy after heroin abuse. Acta Neuropathol (1997) 1.07
How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. J Neural Transm (Vienna) (2006) 1.07
Thymoma: update for the new millennium. Oncologist (2001) 1.06
Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Methods (2001) 1.06
Cancer of the esophagus and gastric cardia: recent advances. Dis Esophagus (2004) 1.06
Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol (2000) 1.06
Proteinase-K-resistant prion protein isoforms in Gerstmann-Sträussler-Scheinker disease (Indiana kindred). J Neuropathol Exp Neurol (1996) 1.04
Four novel cases of periaxin-related neuropathy and review of the literature. Neurology (2010) 1.04
Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol (2001) 1.04
CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer (1997) 1.03
Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer (1993) 1.03